Evidence map›Paper›PMID 31965023›Full record

ArticleScientific reports2020

Human liver stem cells express UGT1A1 and improve phenotype of immunocompromised Crigler Najjar syndrome type I mice.

Elvira Smeralda Famulari, Victor Navarro-Tableros, Maria Beatriz Herrera Sanchez, Giulia Bortolussi, Marta Gai, Laura Conti, Lorenzo Silengo, Emanuela Tolosano, Ciro Tetta, Andrés Fernando Muro and 3 more

Open access · goldAbstract readVideo-Audio Media
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. [Correlation between the mutation spectrum of the UGT1A1 gene and clinical phenotype in patients with inherited hyperunconjugated bilirubinemia].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Base editing: advances and therapeutic opportunities.Nature reviews. Drug discovery · 2020
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Elvira Smeralda Famulari *Molecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Victor Navarro-Tableros *2i3T - Società per la gestione dell'incubatore di imprese e per il trasferimento tecnologico dell'Università degli studi di Torino, Scarl and Molecular Biotechnology Center, Turin, Italy.
Maria Beatriz Herrera Sanchez2i3T - Società per la gestione dell'incubatore di imprese e per il trasferimento tecnologico dell'Università degli studi di Torino, Scarl and Molecular Biotechnology Center, Turin, Italy.
Giulia BortolussiInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
Marta GaiMolecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Laura ContiMolecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0003-1780-098X
Lorenzo SilengoMolecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Emanuela TolosanoMolecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.ORCID http://orcid.org/0000-0002-1622-2340
Ciro TettaUnicyte srl, Turin, Italy.
Andrés Fernando MuroInternational Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.ORCID http://orcid.org/0000-0002-9628-0494
Giovanni CamussiDepartment of Medical Sciences, University of Turin, Turin, Italy.
Sharmila FagooneeInstitute of Biostructure and Bioimaging, CNR c/o Molecular Biotechnology Center, Turin, Italy. sharmila.fagoonee@unito.it.ORCID http://orcid.org/0000-0001-6070-6716
Fiorella AltrudaMolecular Biotechnology Center, Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy. fiorella.altruda@unito.it.
University of Turin · ITInstitute of Molecular Bioimaging and Physiology · ITInternational Centre for Genetic Engineering and Biotechnology · ITInstitute of Biostructure and Bioimaging · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crigler Najjar Syndrome type I (CNSI) is a rare recessive disorder caused by mutations in the Ugt1a1 gene. There is no permanent cure except for liver transplantation, and current therapies present several shortcomings. Since stem cell-based therapy offers a promising alternative for the treatment of this disorder, we evaluated the therapeutic potential of human liver stem cells (HLSC) in immune-compromised NOD SCID Gamma (NSG)/Ugt1

Indexed as

AnimalsBilirubinBrainCell DifferentiationCrigler-Najjar SyndromeDisease Models, AnimalGlucuronosyltransferaseHepatocytesHumansLiverMice, SCIDPhenotypeStem CellsStem Cell TransplantationUGT1A1 EnzymeBilirubinGlucuronosyltransferaseUGT1A1 Enzyme

Identifiers

PMID31965023
PMCPMC6972964
OpenAlexW3005206768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.